Zevra Therapeutics is at the most profitable inflection point in biotechnology: the transition from cash-burning R&D to cash-generating commercial sales. With the recent FDA approval of Miplyffa (for Niemann-Pick disease type C), Zevra has secured the first and only approved treatment for this ultra-rare condition.Read more

A South American farm-and-fertilizer business could become an unexpected safety net for tech-heavy investors if a major weather shift squeezes global food and shipping supply. See how Adecoagro’s fertilizer push and flexible sugar-and-fuel operations may let it benefit from the chaos—while debt and deal integration still loom as key watch-outs.Read more

MindWalk is no longer just a lab-for-hire biotech company; it is building a software platform that helps drug teams predict what molecules will do, and the market may not be keeping up with that shift. The upside hinges on whether big customers adopt its LensAI platform and whether its vaccine and metabolic drug candidates prove out without forcing shareholders to fund endless experiments.Read more

Voyager Technologies owns a big bet on what comes after the International Space Station, and the market may still be treating it like a plain defense supplier. If Starlab stays on track, the business could shift toward steady “rent-like” income from customers in space—but delays or execution missteps could change the story.Read more

AMD may not be the biggest name in AI chips, but big cloud companies want a real backup to Nvidia and are backing AMD so they’re not stuck with one supplier. With new AI chips gaining traction and a growing role in data centers and edge devices, the company could see profits improve—but it still has to prove it can keep up.Read more

Archer Aviation bets that air taxis can move from flashy prototypes to real-world production, helped by Stellantis’ car-making know-how and a factory being built to churn out aircraft at scale. The big swing factor is getting regulators to approve its Midnight aircraft, which could turn today’s high-risk story into an actual commercial launch.Read more

This company is trying to turn a research-stage boron project into a real producer, and the next round of government decisions could make or break that plan. The upside depends on landing major funding and signing firm customer deals, while delays could force more share sales and leave existing investors with much less.Read more

Evaxion Biotech is a micro-cap TechBio company punching significantly above its weight class. While the market views it as a small preclinical player, its proprietary AI-Immunology™ platform has already secured a massive validation: a partnership with Merck (MSD).Read more

Recursion Pharmaceuticals is currently at a critical inflection point. For years, the company was viewed as a "science project"—a high-tech platform promising to revolutionize drug discovery with AI.Read more